Key Updates in Myasthenia Gravis From AANEM 2025 - Medscape Myasthenia gravis updates from AANEM 2025 include efficacy data for efgartigimod, telitacicept, and gefurulimab, plus interim results for a CAR T-cell therapy and DNTH10, an active C1S inhibitor
New Hope for Hard-to-Treat Myasthenia Gravis - Medscape New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited and patients face persistent unmet clinical needs
Myasthenia Gravis Treatment: 5 Things to Know - Medscape Myasthenia gravis (MG) is a rare, acquired autoimmune disorder of the neuromuscular junction, characterized by fatigable muscle weakness in the voluntary muscles Most patients with MG present